Improving outcomes in colorectal cancer: Where do we go from here?

European Journal of Cancer

Volumn 49, Issue 11, 2013, Pages 2476-2485

  Van Cutsem, Eric ^a   Borràs, Josep Maria ^b   Castells, Antoni ^b   Ciardiello, Fortunato ^c   Ducreux, Michel ^d   Haq, Asif ^e   Schmoll, Hans Joachim ^f   Tabernero, Josep ^g  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Biomarkers; Colorectal cancer; Management; Outcomes; Pathogenesis; Survival; Treatment

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; ARRY 438162; BIOLOGICAL MARKER; DABRAFENIB; LGX 818; MSC 1936369B; PIMASERTIB; SELUMETINIB; TIVANTINIB; TIVOZANIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; GENE MUTATION; HEALTH CARE DELIVERY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 84879313900     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.03.026     Document Type: Article

References (73)

1. Globocan. Globocan fact sheet 2008. Available at: < http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 >.
2. American Society for Clinical Oncology. Accelerating progress against cancer. ASCO's blueprint for transforming clinical and translational cancer research. November 2011. Available at: < www.asco.org/./Downloads/Blueprint. pdf >.
3. D. Cunningham, W. Atkin, and H.J. Lenz Colorectal cancer Lancet 375 2010 1030 1047
4. H.E. Karim-Kos, E. de Vries, and I. Soerjomataram Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s Eur J Cancer 44 2008 1345 1389
5. V. Lemmens, L. van Steenbergen, and M. Janssen-Heijnen Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival Acta Oncol 49 2010 784 796
6. J.B. O'Connell, M.A. Maggard, and C.Y. Ko Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging J Natl Cancer Inst 96 2004 1420 1425
7. F.L. Greene, A.K. Stewart, and H.J. Norton A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients Ann Surg 236 2002 416 421
8. K.W. Jasperson, T.M. Tuohy, D.W. Neklason, and R.W. Burt Hereditary and familial colon cancer Gastroenterology 138 2010 2044 2058
9. C. Rosty, S. Parry, and J. Young Serrated polyposis: an enigmatic model of colorectal cancer predisposition Path Res Int 2011 2011 157073
10. M. Hadjihannas, M. Bruckner, and B. Jerchow Aberrant Wnt/β-catenin signaling can induce chromosomal instability in colon cancer Proc Natl Acad Sci U S A 103 2006 10,747 10,752
11. R.C. Boland, and A. Goel Microsatellite instability in colorectal cancer Gastroenterology 138 2010 2073 2087
12. W.S. Samowitz, H. Albertsen, and J. Herrick Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer Gastroenterology 129 2005 837 845
13. J.P. Issa CpG island methylator phenotype in cancer Nat Rev Cancer 4 2004 988 989
14. A. Castells, S. Castellví-Bel, and F. Balaguer Concepts in familial colorectal cancer: where do we stand and what is the future? Gastroenterology 137 2009 404 409
15. K.S. Boparai, E.M. Mathus-Vliegen, and J.J. Koornstra Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study Gut 59 2010 1094 1100
16. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
17. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
18. R. Najdi, R. Holcombe, and M. Waterman Wnt signaling and colon carcinogenesis: beyond APC J Carcinog 10 2011 5
19. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
20. A. Krasinskas EGFR signalling in colorectal carcinoma Pathol Res Int 2011 2011 932932
21. T. Yokota Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 12 2012 163 171
22. European Colorectal Cancer Screening Guidelines Working Group European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication Endoscopy 45 2013 51 59
23. N. Segnan, J. Patnick, and L. von Karsa European guidelines for quality assurance in colorectal cancer screening and diagnosis 2010 Publications Office of the European Union Luxembourg p. 1-386
24. H. Brenner, L. Altenhofen, and M. Hoffmeister Eight years of colonoscopic bowel cancer screening in Germany Dtsch Arztebl Int 107 2010 753 759
25. N.N. Baxter, M.A. Goldwasser, and L.F. Paszat Association of colonoscopy and death from colorectal cancer Ann Intern Med 150 2009 1 8
26. E. Quintero, A. Castells, and L. Bujanda Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening N Engl J Med 366 2012 697 706
27. H. Freeman Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance World J Gastroenterol 14 2008 3461 3463
28. J. Burn, A.M. Gerdes, and F. Macrae Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378 2011 2081 2087
29. AJCC cancer staging manual 6th ed. 2002 Springer-Verlag New York Inc. New York
30. H.J. Schmoll, E. Van Cutsem, and A. Stein ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 23 2012 2479 2516
31. S. Kopetz, G.J. Chang, and M.J. Overman Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 2009 3677 3683
32. D. Lambrechts, B. Claes, and P. Delmar VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials Lancet Oncol 13 2012 724 733
33. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
34. E. Van Cutsem, C.H. Köhne, and I. Láng Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
35. L. Diaz, R. Williams, and J. Wu The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540
36. R. Gillies, D. Verduzco, and R. Gatenby Evolutionary dynamics of carcinogenesis and why targeted therapy does not work Nat Rev Cancer 12 2012 487 493
37. S. Misale, R. Yaeger, and S. Hobor Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
38. E. Vilar, and J. Tabernero Cancer: pinprick diagnostics Nature 486 2012 482 483
39. J.C. Bendell, T.S. Bekaii-Saab, and A.L. Cohn Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study Oncologist 17 2012 1486 1495
40. S. Kopetz, J. Desai, and E. Chan PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors J Clin Oncol 28 15s 2010 [abstr. 3534]
41. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
42. A. Prahallad, C. Sun, and S. Huang Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
43. J. Bennouna, I. Lang, and M. Valladares-Ayerbes A phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens Invest New Drugs 29 2011 1021 1028
44. J.D. Hainsworth, C.L. Cebotaru, and V. Kanarev A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens J Thorac Oncol 5 2010 1630 1636
45. J. Yoon, K.-H. Koo, and K.-Y. Choi MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy Cancer Res 71 2010 445 453
46. F. Morgillo, T. Cascone, and E. D'Aiuto Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors Br J Cancer 105 2011 382 392
47. F. Balaguer, A. Link, and J.J. Lozano Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis Cancer Res 70 2010 6609 6618
48. C. Allegra, G. Yothers, and M. O'Connell Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial J Clin Oncol 31 2013 359 364
49. A. De Gramont, E. Van Cutsem, and H.J. Schmoll Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial Lancet Oncol 13 2012 1225 1233
50. D. Sargent, A. Sobrero, and A. Grothey Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 27 2009 872 877
51. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer. Version 3. 2012. Available at: < http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#site >.
52. E. Van Cutsem, B. Nordlinger, and A. Cervantes Advanced colorectal cancer: ESMO clinical practice guidelines for treatment Ann Oncol 21 Suppl. 5 2010 v93 v97
53. M. Banck, and A. Grothey Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer Clin Cancer Res 15 2009 7492 7501
54. B. Jacobs, W. De Roock, and H. Piessevaux Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 27 2009 5068 5074
55. J. Tabernero, A. Cervantes, and F. Rivera Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study J Clin Oncol 28 2010 1181 1189
56. F. Loupakis, L. Pollina, and I. Stasi PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer J Clin Oncol 27 2009 2622 2629
57. J. Lejeune, G. Thibault, and D. Ternant Evidence for linkage disequilibrium between Fcγ RIIIa-V158F and FcγRIIa-H131R polymorphisms in white patients, and for an Fcγ RIIIa-restricted influence on the response to therapeutic antibodies J Clin Oncol 26 2008 5489 5491
58. F. Bibeau, E. Lopez-Crapez, and F. Di Fiore Impact of Fc{γ}RIIa-Fc{γ}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan J Clin Oncol 27 2009 1122 1129
59. A. Bertotti, G. Migliardi, and F. Galimi A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discov 1 2011 508 523
60. H.I. Hurwitz, J. Yi, W. Ince, W.F. Novotny, and O. Rosen The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 2009 22 28
61. W.L. Ince, A.M. Jubb, and S.N. Holden Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab J Natl Cancer Inst 97 2005 981 989
62. A.M. Jubb, H.I. Hurwitz, and W. Bai Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer J Clin Oncol 24 2006 217 227
63. T.J. Price, J.E. Hardingham, and C.K. Lee Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer J Clin Oncol 29 2011 2675 2682
64. R. Figueiras, V. Goh, and A. Padhani The role of functional imaging in colorectal cancer AJR 195 2010 54 66
65. A.L. Thomas, B. Morgan, and J. Drevs Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584 Semin Oncol 30 3 Suppl. 6 2003 32 38
66. D. Catenacci, M. Kzloff, H. Kindler, and B. Polite Personalized colon cancer care in 2010 Semin Oncol 38 2011 284 308
67. D.J. Sargent, H.S. Wieand, and D.G. Haller Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 23 2005 8664 8670
68. M. Buyse, T. Burzykowski, and K. Carroll Progression-free survival is a surrogate for survival in advanced colorectal cancer J Clin Oncol 25 2007 5218 5224
69. E.L. Korn, B. Freidlin, and J.S. Abrams Overall survival as the outcome for randomized clinical trials with effective subsequent therapies J Clin Oncol 29 2011 2439 2442
70. P.A. Tang, S.M. Bentzen, E.X. Chen, and L.L. Siu Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy J Clin Oncol 25 2007 4562 4568
71. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
72. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
73. B. Buecher, and H. Bleiberg Non-systemic chemotherapy in the treatment of colorectal cancer - portal vein, hepatic arterial and intraperitoneal approaches Aliment Pharmacol Ther 15 2001 1527 1541